China and India Manufacturing: Risks and FDA Monitoring in Pharma Supply Chains

When you swallow a pill, you rarely think about where it was made. But behind that small tablet is a global supply chain with real risks-especially when it comes to China and India manufacturing. These two countries produce most of the world’s generic drugs and active pharmaceutical ingredients (APIs), but their paths to quality couldn’t be more different. One is built on scale and cost. The other on compliance and consistency. And the FDA? It’s watching both closely.

Why FDA Monitoring Matters More Than You Think

The U.S. Food and Drug Administration doesn’t just inspect drug factories in America. It sends teams to China, India, and beyond. Why? Because nearly 80% of the world’s generic APIs come from these two countries. That’s not a guess-it’s a fact backed by DrugPatentWatch’s 2023 data. If a factory in Shanghai or Hyderabad cuts corners, it doesn’t just affect local patients. It affects millions in the U.S., Canada, and Europe.

FDA inspections aren’t random. They’re targeted. Facilities with past violations, poor record-keeping, or unexplained contamination risks get flagged first. Between 2020 and 2023, Indian facilities received 30% fewer Form 483 observations-those are the FDA’s official notices of violations-than Chinese ones. That gap didn’t appear overnight. It’s the result of years of investment, training, and regulatory discipline.

India’s Edge: Compliance Over Quantity

India isn’t the biggest manufacturer by volume. China is. But when it comes to FDA approval, India leads. Over 100 Indian pharmaceutical plants are currently FDA-approved. China? Only 28. That’s more than double the number of compliant facilities. And it’s not just about the count. Indian manufacturers have built systems that reduce human error. Bain & Company’s 2024 report found that leading Indian firms use digital monitoring across production lines to catch deviations before they become problems. That’s not just good practice-it’s a competitive advantage.

India’s strength comes from its regulatory DNA. Since the 1970s, its patent laws have encouraged generic drug production. Over time, that pushed companies to align with international standards. Today, more than half of all Asia-Pacific contract research organizations (CROs) are based in India. That means more scientists, engineers, and quality control experts who speak English, understand FDA guidelines, and have worked on U.S.-marketed drugs.

It’s why global pharma companies are shifting toward the China+1 strategy. Instead of relying on one country, they’re adding India as a backup. Why? Because when the FDA shows up at a plant in Mumbai, they’re more likely to walk away satisfied than if they visit a factory in Wuhan.

China’s Strength: Scale, But With Risk

China makes more drugs than any other country. It controls roughly 80% of the global API supply. That’s not a small number-it’s a monopoly. When you need 10 tons of ibuprofen or 500 kilograms of amoxicillin, China is often the only place that can deliver it fast and cheap.

But scale doesn’t equal safety. China’s manufacturing ecosystem is vast, but uneven. Large state-backed firms meet global standards. Smaller private suppliers? Not always. The FDA has issued import alerts against 37% of Chinese pharmaceutical facilities in 2023. That’s nearly double the rate for Indian facilities. These alerts mean shipments are automatically detained at U.S. ports until the company proves the product is safe. That’s not just a delay-it’s a financial hit.

China’s push into biologics and advanced therapies has been aggressive. Its biopharmaceutical market grew at 19.3% annually between 2015 and 2024. That’s impressive. But it’s also a double-edged sword. Biologics are complex. A single batch can cost millions. If quality control slips, the consequences are severe. And with less transparency in reporting, regulators have less visibility into what’s happening on the factory floor.

The Hidden Dependency: India’s API Problem

Here’s the twist no one talks about enough: India depends on China for its own drug ingredients. In FY2024, 72% of India’s bulk drug imports came from China. That’s up from 66% in 2022. So while India exports safe, FDA-approved pills to the U.S., the raw material inside them? Often made in China.

This creates a single point of failure. If China restricts exports-due to politics, natural disaster, or regulatory shutdown-India’s entire supply chain could stall. One sourcing executive at a major U.S. drugmaker told Bain & Company: “We’re racing to fix this. We can’t keep depending on China for the foundation of our products.”

India’s government is trying to fix this. The ‘Make in India’ initiative has poured nearly $3 billion into incentives for domestic API production. But building a chemical plant that meets FDA standards isn’t like building a smartphone factory. It takes years. And the cost? High. Companies are hesitant to invest when they can still buy cheap APIs from China.

What Happens When the FDA Shows Up

FDA inspectors don’t ask for brochures. They want records. Batch logs. Environmental monitoring data. Equipment calibration reports. They check if the same person who mixes the powder also signs off on the final test. If there’s a mismatch, they note it.

Indian facilities tend to have tighter documentation. Their staff are trained on 21 CFR Part 211-the FDA’s quality system rules for drug manufacturing. Chinese facilities? Often rely on older practices. Some still use paper logs. Others don’t track humidity levels in clean rooms. These aren’t minor details. Humidity can ruin a batch. Paper logs can be lost. And once the FDA finds a pattern of issues, they don’t just issue a warning-they block imports.

Between 2020 and 2023, the number of FDA warning letters issued to Chinese manufacturers rose 40%. Meanwhile, India saw a steady decline. That’s not luck. It’s systemic.

The Future: Who Wins?

By 2047, India could be exporting $350 billion in pharmaceuticals. That’s not fantasy. It’s Bain & Company’s projection. But it hinges on two things: reducing reliance on Chinese APIs and moving into higher-value drugs like biosimilars and cell therapies.

China, meanwhile, is losing ground in the eyes of Western regulators. Its share of the outsourced manufacturing market is expected to drop from 25% to 15% by 2030. Why? Because companies are tired of the risk. Even if Chinese factories are cheaper, the cost of recalls, delays, and reputational damage adds up.

India’s advantage isn’t just in its plants. It’s in its people. Its regulatory culture. Its willingness to adapt. China’s advantage? It still holds the keys to the raw materials. But that’s changing. More companies are now investing in Vietnam, Mexico, and even the U.S. to diversify. India is the most ready to step in.

What This Means for You

If you’re a patient, you’re probably safe. The FDA’s system, while imperfect, catches most problems before they reach shelves. But if you’re a pharmacist, a distributor, or a policymaker, you need to understand the real risks. The next drug shortage might not come from a pandemic. It might come from a single factory in China that gets shut down-or from India’s inability to replace its API imports.

The truth? Neither country is perfect. But if you want reliable, safe medicine, India’s compliance track record gives it the edge. China still holds the volume. But volume without quality doesn’t last.